ASK THE EXPERTS

PROSTATE CANCER GENETICS: EXPERTS DISCUSS RISK, SCREENING AND TREATMENT

"FORCE improves the lives of the millions of individuals and families facing hereditary breast, ovarian, pancreatic, prostate, colorectal and endometrial cancers.

FORCE Programs

Support

Personalized Peer Support

Virtual Support Groups

Private Facebook Group and Message Boards

Helpline

Advocacy & Public Policy

State & Federal Advocacy Efforts

Advocacy Day

Patient Advocate Leader Training

Take Action Campaigns



Education

Information on Genes & Hereditary Cancers

XRAY – Behind the Cancer Headlines

Educational Brochures & Decision Guides

Ask the Experts Webinar Series

Research

Research Matching and Targeted Study Promotion

Researcher Training, Assistance and Collaborations

Research Advocate Training

FORCE
Facing Hereditary Cancer EMPOWERED

Proprietary and Confidential. All Rights Reserved.

Thank You to our sponsors!

Presenting Sponsor

AstraZeneca

Proprietary and Confidential. All Rights Reserved.

Thank You to our sponsors!

Empowerment Sponsors

Proprietary and Confidential. All Rights Reserved.

Thank You to our sponsors!

Affinity Sponsors

Proprietary and Confidential. All Rights Reserved.

Thank You to our sponsors!

Community Sponsors

FOUNDATION MEDICINE

Pfizer Oncology

Proprietary and Confidential. All Rights Reserved.

Ask the Experts

FORCE

Facing Hereditary Cancer EMPOWERED

1. **Expert interviews**
   This portion will be recorded.

2. **Breakout sessions**
   Group discussion and question and answers.

Proprietary and Confidential. All Rights Reserved.

Speakers

Rana McKay, MD

Medical Oncologist

UC San Diego

Jason Hafron, MD

Urologist

Michigan Institute of Urology

Angela Trepanier, CGC

Genetic Counselor

Wayne State School of Medicine

Proprietary and Confidential. All Rights Reserved.

Breakout Rooms



Breakout Room 1
Research and
Clinical Care



Breakout Room 2
Support and
Resources



Breakout Room 3
Prostate Cancer Public
Policy and Advocacy

FORCE
Facing Hereditary Cancer EMPOWERED

Proprietary and Confidential. All Rights Reserved.

QR codes

Use the camera on your phone to scan, open links, and bookmark pages

Need technical assistance?

Email: Eliseb@facingourrisk.org

Resources

Click on "more" to open up the resource tab.



Breakout Rooms

Once the breakout rooms are open, a breakout room icon will appear on your control setting bar.



Section 1

Prostate Cancer Risk

Genes Associated with Prostate Cancer Risk

Genes with strong evidence	Genes with emerging evidence
BRCA2, BRCA1, HOXB13, and TP53	ATM, CHEK2, PALB2, and the Lynch syndrome genes (MSH2, MSH6, MLH1, PMS2, EPCAM)

FORCE
Facing Hereditary Cancer EMPOWERED

Proprietary and Confidential. All Rights Reserved.

Study for Men at High Genetic Risk for Prostate Cancer

Screening Studies: facingourrisk.org/research

NCI: Screening Study for Men at High Genetic Risk for Prostate Cancer

FORCE
Facing Hereditary Cancer EMPOWERED

Proprietary and Confidential. All Rights Reserved.

FORCE Information on BRCA2, BRCA1, ATM and Lynch Syndrome

BRCA2

BRCA1

ATM

Lynch Syndrome

FORCE
Facing Hereditary Cancer EMPOWERED

Proprietary and Confidential. All Rights Reserved.

Discuss genetic testing with your doctor if you have prostate cancer and:

- ✔ Metastatic or high-risk/very high-risk prostate cancer
- ✔ Eastern European Jewish Ancestry
- ✔ A relative who tested positive for an inherited mutation
- ✔ Close relative/s with breast cancer at or before age 50; or male breast, ovarian, pancreatic, metastatic or high-risk prostate cancer at any age
- ✔ Three or more relatives on same side of family with prostate cancer at any age
- ✔ Diagnosed at 55 or younger, or have intermediate-risk prostate cancer with "intraductal cribiform" histology

Section 2

Prostate Cancer Screening

FORCE Prostate Cancer Screening Resources

Prostate Screening Options

bit.ly/force-prostate-screening

Prostate Screening Guidelines

bit.ly/force-prostate-screening-guidelines

FORCE
Facing Hereditary Cancer EMPOWERED

Proprietary and Confidential. All Rights Reserved.

Definition

Multiparametric MRI (MPMRI) is a special type of imaging that can create a more detailed map of the prostate.

Proprietary and Confidential. All Rights Reserved.

Definition

Shared decision making is a process in which both the patient and health care provider work together to decide the best plan of care for the patient. When making a shared decision, the patient's values, goals, and concerns are considered.

Proprietary and Confidential. All Rights Reserved.

Prostate Cancer Screening Clinical Trials

Screening Studies: facingourrisk.org/research

PATROL
Prostate Cancer Screening for People AT Genetic Risk FOr Aggressive Disease

PATROL Study: Prostate Cancer Screening for People AT Genetic Risk for Aggressive Disease

NCI: Screening Study for Men at High Genetic Risk for Prostate Cancer

Upright MRI for Prostate Cancer Screening

bitly

Prostate Screening Studies

Proprietary and Confidential. All Rights Reserved.

Section 3

Prostate Cancer Diagnosis

Section 4

Prostate Cancer Treatment

Definitions

- **Active surveillance** refers to intensive monitoring of localized prostate cancer with the goal to treat to cure if cancer progresses.
- **Watchful waiting** involves less intensive monitoring with a focus on symptom management. Watchful waiting may be used for patients for whom the risks of treatment outweigh the benefits.

Proprietary and Confidential. All Rights Reserved.

FORCE Prostate Cancer Treatment Resources

Treatment

bit.ly/force-prostate-treatment

Biomarkers

bit.ly/force-prostate-biomarkers

Targeted & Immunotherapies

bit.ly/force-targeted-therapy-prostate

FORCE
Facing Hereditary Cancer EMPOWERED

Proprietary and Confidential. All Rights Reserved.

PARP Inhibitors Approved for Advanced Prostate Cancer Treatment

bit.ly/force-targeted-therapy-prostate

	Olaparib	Rucaparib	Talazoparib	Niraparib
Potency at PARP 1	++	+++	+++	+
Monotherapy	Yes	Yes	No	No
FDA Indication	For HRR	For BRCA 1/2	Not Applicable	Not Applicable
Combination	Yes With Abiraterone	No	Yes With Enzalutamide	Yes With Abiraterone
FDA Indication	BRCA 1/2	Not Applicable	HRR	BRCA 1/2

NePtune Study

Treatment Studies and Registry: facingourrisk.org/research

NePtune: Using PARP Inhibitors Before Surgery in Localized Prostate Cancer

bit.ly/force-neptune-study

Proprietary and Confidential. All Rights Reserved.

NePtune Study Eligibility

- Provide written informed consent and HIPPA authorization (a detailed document which explains specific uses and disclosures of protected health information) of personal health information prior to registration.
- Must have evidence of an inherited or acquired ATM, BRCA1, BRCA2, CHEK2, PALB2, RAD51B, RAD51C, RAD51D, RAD54L2, BARD1, FANCA, BRIP1 mutation.
- Are candidates for a radical prostatectomy.

NePtune Eligibility

bit.ly/force-neptune-study

FORCE
Facing Hereditary Cancer EMPOWERED

Proprietary and Confidential. All Rights Reserved.

FORCE Prostate Cancer Treatment Resources

Treatment

bit.ly/force-prostate-treatment

Biomarkers

bit.ly/force-prostate-biomarkers

Targeted & Immunotherapies

bit.ly/force-targeted-therapy-prostate

Proprietary and Confidential. All Rights Reserved.

Section 5

Advanced-Stage Prostate Cancer Treatment

EvoPAR-PR01

bit.ly/force-evopar-pr01

PRINTER FRIENDLY PAGE

Studying the Effectiveness of New PARP Inhibitor, Saruparib Compared to Current Treatment Options for Metastatic Prostate Cancer EvoPAR-PRO1

Clinicaltrials.gov identifier:
NCT06120491

Treatment
Treatment study for metastatic, castration-sensitive prostate cancer

Study Contact Information:
For additional information, please contact:

AstraZeneca Clinical Study Information Center

1-877-240-9479
or information.center@astrazeneca.com

Principal Investigator: Kim Nguyen Chi, MD, BC Cancer, Canada

Principal Investigator: Arun Azad, MD, Peter

This Study is Open To:

People 18 years or older, who meet the following:

- castration-sensitive prostate cancer
- metastatic disease
- have not received treatment in the metastatic setting (with some exceptions)
- have one of the following mutations in their tumor found by tumor testing or liquid biopsy:
  - BRCA1, BRCA2, ATM, BARD1, CDK12, PALB2, RAD51B, RAD51C, RAD51D

Definitions

- **Castration-sensitive prostate cancer** refers to cancer that still responds to testosterone suppression (hormone therapy).
- **Castration-resistant prostate cancer** refers to cancer that still grows despite very low testosterone levels.

Proprietary and Confidential. All Rights Reserved.

Definitions

- **Radioligand therapy** refers to a type of targeted treatment that delivers radiation directly to cancer cells.
- **Antibody-drug conjugates** refer to a type of targeted treatment where antibodies find the cancer cells and release the chemotherapy only where needed.
- **Biospecific antibodies** are a type of immunotherapy that forces the cancer cells together with immune cells in order to kill the cancer cells.

Proprietary and Confidential. All Rights Reserved.

Clinical Trials for Advanced Prostate Cancer



LEGION-100 Trial

Clinical Trials for Advanced Prostate Cancer

MEVPRO

Pfizer Clinical Trials for Metastatic Prostate Cancer

bit.ly/force-mevpro

Treating Advanced Cancers with DNA-Repair Mutations Using MOMA-313 Alone or In Combination with the PARP Inhibitor Olaparib

bit.ly/force-moma-313

Closing Thoughts

Thank You! Please Complete our Short Feedback Survey

bit.ly/experts-prostate-feedback

FORCE
Facing Hereditary Cancer EMPOWERED

Proprietary and Confidential. All Rights Reserved.

Join Us for our Next Hereditary Cancer Update

July 22, 2025 at 2 pm

bit.ly/force-updates

FORCE
Facing Hereditary Cancer EMPOWERED

Proprietary and Confidential. All Rights Reserved.

Connect with us

www.FacingOurRisk.org

866-266-RISK

Info@FacingOurRisk.Org

FORCE
Facing Hereditary Cancer EMPOWERED

Proprietary and Confidential. All Rights Reserved.